These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20073450)

  • 41. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration.
    Yokoyama T; Miyazawa K; Kurakawa E; Nagate A; Shimamoto T; Iwaya K; Akata S; Aoshima M; Serizawa H; Ohyashiki K
    Leukemia; 2004 Mar; 18(3):645-6. PubMed ID: 14724651
    [No Abstract]   [Full Text] [Related]  

  • 42. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty.
    Mariani S; Basciani S; Fabbri A; Agati L; Ulisse S; Lubrano C; Spera G; Gnessi L
    Fertil Steril; 2011 Mar; 95(3):1120.e15-7. PubMed ID: 20888557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?
    Distler JH; Distler O
    Ann Rheum Dis; 2007 Jun; 66(6):836. PubMed ID: 17513571
    [No Abstract]   [Full Text] [Related]  

  • 44. Adverse effects of imatinib--dissecting heart from the rest.
    Thachil J
    Cancer; 2011 Jan; 117(1):228; author reply 228-9. PubMed ID: 20806351
    [No Abstract]   [Full Text] [Related]  

  • 45. Lichenoid drug eruption related to imatinib: report of a new case and review of the literature.
    Sendagorta E; Herranz P; Feito M; Ramírez P; Feltes R; Floristán U; Mariño-Enriquez A; Casado M
    Clin Exp Dermatol; 2009 Oct; 34(7):e315-6. PubMed ID: 19456782
    [No Abstract]   [Full Text] [Related]  

  • 46. Reversible hair depigmentation in a patient treated with imatinib.
    Mariani S; Abruzzese E; Basciani S; Fiore D; Persichetti A; Watanabe M; Spera G; Gnessi L
    Leuk Res; 2011 Jun; 35(6):e64-6. PubMed ID: 21176848
    [No Abstract]   [Full Text] [Related]  

  • 47. Keratoacanthomas associated with imatinib mesylate.
    Balagula Y; Busam KJ; Carvajal RD; Wolchok JD; Myskowski PL
    Acta Oncol; 2011 May; 50(4):593-5. PubMed ID: 21108567
    [No Abstract]   [Full Text] [Related]  

  • 48. More on ovarian insufficiency with imatinib.
    Malozowski S; Nelson L; Calis KA
    N Engl J Med; 2008 Jun; 358(24):2648; author reply 2648-9. PubMed ID: 18550885
    [No Abstract]   [Full Text] [Related]  

  • 49. Is imatinib-related cardiotoxicity still an open issue?
    Breccia M
    Leuk Res; 2011 Jan; 35(1):34-5. PubMed ID: 20961615
    [No Abstract]   [Full Text] [Related]  

  • 50. Imatinib: the controversial discussion on cardiotoxicity induced by endoplasmic reticulum (ER) stress.
    Marchan R; Bolt HM
    Arch Toxicol; 2012 Mar; 86(3):339-40. PubMed ID: 22327847
    [No Abstract]   [Full Text] [Related]  

  • 51. Gleevec may be heart toxic.
    Duke Med Health News; 2007 Jan; 13(1):2. PubMed ID: 17299882
    [No Abstract]   [Full Text] [Related]  

  • 52. [Adverse drug reactions induced by molecular target therapy].
    Kano Y
    Arerugi; 2007 Dec; 56(12):1485-91. PubMed ID: 18195551
    [No Abstract]   [Full Text] [Related]  

  • 53. Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection.
    Jasielec JK; Larson RA
    J Clin Oncol; 2016 Feb; 34(6):e46-8. PubMed ID: 24958829
    [No Abstract]   [Full Text] [Related]  

  • 54. Pulmonary toxicities from targeted therapies: a review.
    Barber NA; Ganti AK
    Target Oncol; 2011 Dec; 6(4):235-43. PubMed ID: 22076388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapy-induced toxicity of the lungs: an overview.
    Charpidou AG; Gkiozos I; Tsimpoukis S; Apostolaki D; Dilana KD; Karapanagiotou EM; Syrigos KN
    Anticancer Res; 2009 Feb; 29(2):631-9. PubMed ID: 19331213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antineoplastic therapy-induced pulmonary toxicity.
    Sadowska AM; Specenier P; Germonpre P; Peeters M
    Expert Rev Anticancer Ther; 2013 Aug; 13(8):997-1006. PubMed ID: 23984900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of pulmonary toxicity associated with targeted anticancer therapies.
    Teuwen LA; Van den Mooter T; Dirix L
    Expert Opin Drug Metab Toxicol; 2015; 11(11):1695-707. PubMed ID: 26293379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pulmonary complications of novel antineoplastic agents for solid tumors.
    Vahid B; Marik PE
    Chest; 2008 Feb; 133(2):528-38. PubMed ID: 18252919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.
    Eskazan AE
    Acta Oncol; 2019 Jan; 58(1):123-124. PubMed ID: 30106325
    [No Abstract]   [Full Text] [Related]  

  • 60. Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review.
    Lehne G; Lote K
    Acta Oncol; 1990; 29(2):113-24. PubMed ID: 2185802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.